INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
Public company

VIRVir Biotechnology, Inc.

CIK 0001706431

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 2
Max Insider Score21
Connections4with evidence

VIR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
DV
de Verneuil VaninaEVP, General Counsel, Corp Sec
VIRVir Biotechnology, Inc.
Open-market sale · 10b5-1 plan
SELL$15K
1,343 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    de Verneuil VaninaEVP, General Counsel, Corp Sec · Nov 4, 2026
  • ← Insider ofevidence
    Topalian Suzanne LouiseDirector · Oct 28, 2026
  • ← Lobbied forevidence
    FORBES-TATELDA Q1 2026 first quarter · Health issues · Aug 26, 2026
1
DV
de Verneuil VaninaEVP, General Counsel, Corp Sec
VIRVir Biotechnology, Inc.
Open-market sale · 10b5-1 plan
SELL
$27K
2,407 sh
Nov 3, 2026
Nov 4, 2026
traded Nov 3, 2026
+1d
SEC FORM 4

Evidence

9
TL
Topalian Suzanne LouiseDirector
VIRVir Biotechnology, Inc.
Grant or award
A—
8,000 sh
Oct 27, 2026Oct 28, 2026
traded Oct 27, 2026
+1dSEC FORM 4

Evidence

21
TL
Topalian Suzanne LouiseDirector
VIRVir Biotechnology, Inc.
Grant or award
A—
4,731 sh
Oct 27, 2026Oct 28, 2026
traded Oct 27, 2026
+1dSEC FORM 4

Evidence

9
TL
Topalian Suzanne LouiseDirector
VIRVir Biotechnology, Inc.
Grant or award
A—
16.0K sh
Oct 27, 2026Oct 28, 2026
traded Oct 27, 2026
+1dSEC FORM 4

Evidence

21
TL
Topalian Suzanne LouiseDirector
VIRVir Biotechnology, Inc.
Grant or award
A—
9,462 sh
Oct 27, 2026Oct 28, 2026
traded Oct 27, 2026
+1dSEC FORM 4

Evidence

Lobbying

$100K reported · de-duplicated
2026 Q2 $50K via firms2026 Q1 $50K via firms
  • FORBES-TATE$50K2026 Q1 · posted Aug 26, 2026 · Health issues
  • FORBES-TATE$50K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.